Chong Kun Dang Pharmaceutical (XKRX:185750) Additional Paid-In Capital : ₩261,969 Mil(As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Additional Paid-In Capital?

Chong Kun Dang Pharmaceutical's quarterly additional paid-in capital stayed the same from Sep. 2023 (₩263,484 Mil) to Dec. 2023 (₩263,484 Mil) and stayed the same from Dec. 2023 (₩263,484 Mil) to Mar. 2024 (₩261,969 Mil).

Chong Kun Dang Pharmaceutical's annual additional paid-in capital declined from Dec. 2021 (₩266,340 Mil) to Dec. 2022 (₩264,935 Mil) and declined from Dec. 2022 (₩264,935 Mil) to Dec. 2023 (₩263,484 Mil).

Chong Kun Dang Pharmaceutical Additional Paid-In Capital Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Additional Paid-In Capital Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

268,979.57

267,754.76

266,340.05

264,935.20

263,484.14

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															263,484.14	263,484.14	263,484.14	263,484.14	261,969.25

Chong Kun Dang Pharmaceutical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Chong Kun Dang Pharmaceutical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines